Primary Hypercholesterolemia Terminated Phase 2 Trials for Implitapide (DB04852)

Also known as: Type IIa hyperlipidaemia / Dyslipidemia (Fredrickson Type Ⅱa) / Type IIa Hypercholesterolemia / Primary Hypercholesterolaemia / Familial Hypercholesterolaemia / Familial Hypercholesterolemia / Hypercholesterolemia, Familial / Type IIa hyperlipoproteinemia / Hyperlipoproteinemia Type IIa / Fredrickson Type IIa hyperlipoproteinemia / Type IIa hyperlipoproteinaemia / Pure hypercholesterolemia / Fredrickson Type IIa hyperlipoproteinaemia / Fredrickson Type IIa hyperlipidemia / Fredrickson Type IIa hyperlipidaemia / Fredrickson Type IIa lipidemia / Fredrickson Type IIa lipidaemia / Type IIa hyperlipidemia / Type II lipidemia / Type II lipidaemia / Hyperlipoproteinemia Type II / Type II hyperlipoproteinaemia / Type II hyperlipoproteinemia / Fredrickson Type II hyperlipidaemia / Fredrickson Type II lipidemia / Fredrickson Type II hyperlipidemia / Type II hyperlipidaemia / Fredrickson Type II lipidaemia / Type II hyperlipidemia

IndicationStatusPhase
DBCOND0033454 (Primary Hypercholesterolemia)Terminated2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00079846Implitapide in Patients With Homozygous Familial Hypercholesterolemia (HoFH) on Maximal Concurrent Lipid-Lowering TherapyTreatment
NCT00079859Implitapide in Patients With Heterozygous Familial Hypercholesterolemia (HeFH) on Maximal Concurrent Lipid-Lowering TherapyTreatment